DNAe to present new data on transformative AMR and oncology diagnostics at AMP 2024

• Posters will present data on rapid, near-patient tests* targeting bloodstream infection / antimicrobial resistance (BSI/AMR) and oncology applications

• Pioneering sample-to-report diagnostic technology set to transform clinical care pathways ‍

London, UK and Carlsbad, CA, USA – 20th November 2024 – DNAe, the next generation sequencing (NGS) company developing a novel diagnostics platform for use at the point-of-need, announces that it will be presenting new clinical data on testing applications in cancer monitoring, bloodstream infection (BSI) detection and combatting antimicrobial resistance (AMR) at the 30th Anniversary Association for Molecular Pathology (AMP) Annual Meeting and Expo – to be held November 19th – 23rd at the Vancouver Convention Center, Canada. The two posters to be presented at AMP 2024 have also been accepted for publication in the November issue of The Journal of Molecular Diagnostics.

DNAe has been developing a direct-from-sample, diagnostic sequencing platform that is user-friendly and suitable for operation at the point of need (including in community hospitals, STAT labs, and clinics), to provide comprehensive actionable information to clinicians in a matter of hours, versus days. The company is actively developing a pipeline of tests in infectious disease, oncology and beyond. DNAe’s first diagnostic test will be an unprecedented test for sepsis / bloodstream infections and antimicrobial resistance, which is unique in providing comprehensive and actionable clinical results directly from whole blood specimens within a work shift.

Also in the development pipeline, DNAe is applying its platform to cancer monitoring. By detecting and sequencing tumor DNA, minimally-invasively, in a matter of hours, DNAe’s platform has the potential to detect unresponsive or recurrent cancer earlier.

Samuel Reed, CEO of DNAe, commented: “We are very much looking forward to sharing these exciting datasets with the global community at AMP 2024. Our LiDia-SEQ™ platform is now on an accelerated commercial pathway that will deliver truly transformative testing capabilities at the point of need – from rapid infectious disease diagnostics to new insights for cancer testing and monitoring and beyond.”

Poster Presentations at AMP 2024

Direct Detection of Bloodstream Pathogens from Whole Blood using the Workflow for BSI/AMR Test: The First, NGS Sample-to-Result Solution
Category: Infectious Diseases
Presenter: Michele Wisniewski – Senior Director, NGS Assay Development, DNAe
Saturday, 23rd November 2024, 9:15am – 10:15am PST

Rapid Automated Circulating Tumor DNA (ctDNA) Enrichment Directly from Plasma
Category: Solid Tumors
Presenter:  Jarrett Killpack – Scientist, DNAe
Friday, 22nd November 2024, 9:15am – 10:15am PST

To schedule a meeting with the DNAe team for an update on the LiDia-SEQ™ platform, please contact marketing@dnae.com.

– ENDS –

Contact details

DNAe

Samuel Reed, CEO, DNAe Group

Supriya Mathur, Global Head of Communications

Tel: +44 (0) 20 7036 2100 Email: supriya.mathur@dnae.com

About DNAe (www.dnae.com)

DNAe is commercializing its pioneering semiconductor sequencing technology for healthcare applications where rapid point-of-need diagnostics are of critical need, including infectious disease and cancer testing and monitoring. It is developing the LiDia-SEQ™ system, a user-friendly, direct-from-specimen platform that performs genomic analysis on a microchip, to provide comprehensive, actionable information to clinicians in a matter of hours, versus days. DNAe’s initial focus is on infectious disease diagnostics, starting with a groundbreaking test for bloodstream infections (BSI) and antimicrobial resistance (AMR), which uses whole blood specimens to directly detect and identify infections that lead to sepsis. This will provide clinicians with actionable information to help select the appropriate antibiotics to treat the disease. A pipeline of follow-on tests is in development for viruses and cancer testing and monitoring. DNAe has received “Breakthrough Device” designation from the US Food and Drug Administration (FDA) for its pioneering platform and first assay.

A private company, DNAe has operations in London, UK and Carlsbad, CA, USA. DNAe has received funding from The Biomedical Advanced Research and Development Authority (BARDA)** to develop its diagnostic platform, initially for antimicrobial-resistant infections. DNAe’s major shareholder is Genting Berhad, a Malaysian-based global investor with a growing portfolio of investments in cutting-edge life sciences companies.

Follow us on LinkedIn, X, Instagram

*Disclaimer: The DNAe BSI/AMR test and LiDia-SEQTM platform are under development and have not been approved or cleared by the FDA or any other regulatory agency.

**This project has been supported in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number HHSO100201600017C.

About sepsis

Sepsis, which was often called “blood poisoning”, is the body’s overwhelming and life-threatening response to infection which can lead to tissue damage, organ failure, and death. Despite the best antibiotics and intensive care, sepsis is the primary cause of death from infection. Every three seconds, someone in the world dies of sepsis; globally sepsis claims 11 million lives a year ^i,ii. Sepsis cases are increasing, up by between 8% and 13%i over the last decade, claiming more lives than bowel and breast cancer combinedⁱⁱⁱ. Organizations like The UK Sepsis Trust (UKST) and Sepsis Alliance work tirelessly to fight this life-threatening condition, stop preventable deaths and support those affected by sepsis.